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ABSTRACT: O-GlcNAc transferase (OGT) catalyzes the installation of N-acetylglucosamine (GlcNAc) O-linked to
nucleocytoplasmic proteins (O-GlcNAc) within multicellular eukaryotes. OGT shows surprising tolerance for structural changes
in the sugar component of its nucleotide sugar donor substrate, uridine diphosphate N-acetylglucosamine (UDP-GlcNAc). Here,
we find that OGT uses UDP-glucose to install O-linked glucose (O-Glc) onto proteins only 25-fold less efficiently than O-
GlcNAc. Spurred by this observation, we show that OGT transfers 2-azido-2-deoxy-D-glucose (GlcAz) in vitro from UDP-GlcAz
to proteins. Further, feeding cells with per-O-acetyl GlcAz (AcGlcAz), in combination with inhibition or inducible knockout of
OGT, shows OGT-dependent modification of nuclear and cytoplasmic proteins with O-GlcAz as detected using microscopy,
immunoblot, and proteomics. We find that O-GlcAz is reversible within cells, and an unidentified cellular enzyme exists to cleave
O-Glc that can also process O-GlcAz. We anticipate that AcGlcAz will prove to be a useful tool to study the O-GlcNAc
modification. We also speculate that, given the high concentration of UDP-Glc within certain mammalian tissues, O-Glc may
exist within mammals and serve as a physiologically relevant modification.
The modification of serine and threonine residues ofnucleocytoplasmic proteins with β-O-linked N-acetylglu-
cosamine (O-GlcNAc) is widespread and conserved among
metazoans. O-GlcNAc has been implicated in the diverse
cellular processes ranging from transcription1 to stress
response.2 Imbalances in O-GlcNAc levels have accordingly
been implicated in various diseases including, for example,
Alzheimer disease3 and cancer.4 Two carbohydrate-processing
enzymes act to regulate cellular O-GlcNAc levels. The enzyme
catalyzing the installation of O-GlcNAc using uridine
diphosphate-α-N-acetyl-D-glucosamine (UDP-GlcNAc) as the
glycosyl donor is the glycosyltransferase uridine diphosphate-N-
acetyl-D-glucosamine: polypeptidyl transferase (OGT).5 The
enzyme responsible for catalyzing the removal of O-GlcNAc is
the glycoside hydrolase known as O-GlcNAcase (OGA).5
Given the important and wide ranging roles played by O-
GlcNAc, there is considerable interest in understanding the
substrate specificities5−8 of these enzymes as well as the
development of chemical probes that can be used to interrogate
the function of O-GlcNAc.7,9−13
Supporting a critical conserved role in cell function, OGT is
present within all eukaryotes and in all mammalian tissues as
two isoforms, which arise from alternative splicing of the OGT
gene.5 Recently, the structure of a major fragment of human
OGT (hOGT) was reported, comprising the C-terminal
catalytic domain and the first 4.5 tetratricopeptide repeats
(TPRs) of the N-terminal TPR-containing region.14,15 The
structure of this hOGT construct in a ternary complex15 with
uridine diphosphate-N-acetyl-D-5-thioglucosamine (UDP-
5SGlcNAc),16 an incompetent substrate analogue of UDP-
GlcNAc, and a peptide substrate reveals details of active site
enzyme−substrate interactions. This model indicates that the
nitrogen of the acetamide group of UDP-5SGlcNAc hydrogen
bonds with one of the β-phosphate oxygens of the diphosphate
moiety and its carbonyl group hydrogen bonds with His498.
Notably, site-directed mutagenesis of His498 impairs OGT
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activity,17 consistent with this model and supporting a critical
role for the acetamido group in catalysis.14
Here, we describe our surprising observation that OGT could
transfer glucose from uridine diphosphate-D-glucopyranose
(UDP-glucose, UDP-Glc) to the well-known OGT substrate
nucleoporin 62 (Nup62).18,19 Stimulated by this observation,
we went on to show that uridine diphospho-2-azido-2-deoxy-α-
D-glucopyranose (UDP-GlcAz) serves as a substrate of hOGT
in vitro. We further demonstrated that feeding cells with 1,3,4,6-
tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranose (AcGlcAz) re-
sulted in labeling of cellular proteins, including Nup62, with O-
linked 2-azido-2-deoxy-β-D-glucose (O-GlcAz). Given the
distribution of O-GlcAz-labeled proteins within cells, as
assessed by microscopy, in conjunction with the identity of
proteins metabolically labeled with GlcAz established using
mass spectrometry (MS) proteomics, we conclude that OGT
shows surprising substrate promiscuity and that AcGlcAz can
be assimilated within cells to label nuclear and cytoplasmic
proteins in place of O-GlcNAc. We anticipate that this
metabolic labeling substrate may prove useful to study the
roles of O-GlcNAc and aid in identification of specific subsets
of O-GlcNAc glycosylated proteins. Finally, these data suggest
OGT is more promiscuous than previously recognized and may
catalyze modification of proteins with naturally occurring sugars
other than O-GlcNAc, such as O-Glc.
■ RESULTS AND DISCUSSION
UDP-Glc and UDP-GlcAz Are Substrates of OGT.
During routine in vitro assays to monitor hOGT transferase
activity using UDP-[3H]GlcNAc,6,17 we unexpectedly observed
glucosyltransferase activity when using UDP-[3H]Glc as a
negative control donor substrate with Nup62 as the acceptor
protein (Figure 1A and B). To test whether the UDP-[3H]Glc
might be contaminated with UDP-[3H]GlcNAc we performed
immunoblot using anti-O-GlcNAc antibody and found there
was no detectable immunoreactivity against [3H]Glc-modified
Nup62 (Supporting Figure 2). We also performed parallel
kinetic studies using UDP-[3H]Glc and UDP-[3H]GlcNAc
(Figure 1C). For UDP-Glc, we find kcat and Km values that are
distinct from the values obtained using UDP-GlcNAc as the
donor substrate (Figure 1C). These data indicate there was no
contamination of the commercial supply of UDP-Glc. Notably,
we observe that the second order rate constant (kcat/Km) for
UDP-Glc as a donor substrate was only 25-fold lower than that
measured when using UDP-GlcNAc. The major difference in
kcat/Km values stemmed from the 13-fold higher Km value for
UDP-Glc as compared to UDP-GlcNAc, which is consistent
with the 2-acetamido group forming binding interactions with
the hOGT active site.
We therefore speculated that hOGT might tolerate
replacement of the 2-acetamido substituent and considered
whether a group incapable of hydrogen bonding to the enzyme
would be tolerated. We therefore synthesized uridine
Figure 1. UDP-Glc and UDP-GlcAz, competent nucleotide sugar donor substrates for hOGT in vitro. (A) Schematic showing the hOGT catalyzed
glycosyl transfer using different nucleotide sugar donor substrates. (B) Blotting of Nup62 incubated with hOGT and radiolabeled UDP-Glc and
UDP-GlcNAc (4 μM, left panel) or UDP-GlcAz and UDP-GlcNAz (100 μM, right panel) as sugar donor substrates. hOGT catalyzed transfer of
[3H]-UDP-GlcNAc and UDP-GlcNAz at the same concentrations used for UDP-Glc and UDP-GlcAz, respectively. CuAAC labeling of GlcAz and
GlcNAz labeled proteins was performed using alkyne-diazo-biotin and visualization using streptavidin IRdye. (C) Kinetic analysis of the hOGT
catalyzed transfer of UDP-GlcNAc (closed circles) and UDP-Glc (closed squares) at various concentrations using a fixed Nup62 concentration (10
μM). The resulting kinetic parameters are summarized in the table. The data are displayed as an average of quadruplicate determinations with
associated standard deviations shown as error bars.
diphosphate-2-azido-2-deoxy-D-glucopyranose (UDP-GlcAz,
Figure 1A, Supporting Figure 1, and Supporting Methods)
and uridine diphosphate-2-azidoacetyl-2-deoxy-D-glucopyra-
nose (UDP-GlcNAz, Figure 1A).9 We used these compounds
as substrates for hOGT using chemoselective copper-catalyzed
azide−alkyne cycloaddition (CuAAC)20,21 to detect transfer of
the sugar moiety onto protein substrates. Both GlcAz and
GlcNAz were transferred onto Nup62 with, as expected given
the second order rate constants for UDP-GlcNAc versus UDP-
Glc (Figure 1C), a strong preference for UDP-GlcNAz over
UDP-GlcAz (Figure 1B, right panel). Previous reports indicate
that the different reactivities20,21 of the primary and secondary
azide moieties of these donor sugars should not significantly
affect the coupling reaction, suggesting that the click chemistry
used here should not contribute significantly to errors in these
observations.
We were curious whether human OGA (hOGA), a β-
glucosidase, or mammalian cell lysates might be able to remove
either O-Glc or O-GlcAz from proteins. We thus incubated
recombinant Nup62, modified using either UDP-[3H]GlcNAc
or UDP-[3H]Glc, with hOGA, sweet almond β-glucosidase, and
COS-7 crude cell lysates (Figure 2A). We find as expected that
hOGA could remove [3H]GlcNAc but left [3H]Glc attached to
the Nup62. The β-glucosidase processed neither substrate;
however, [3H]Glc was removed from Nup62 in vitro at neutral
pH in the presence of COS-7 cell lysates, suggesting there may
be a cellular β-glucosidase that might prevent adventitious
formation of O-Glc within cells. We next evaluated several
proteins known to be O-GlcNAc modified including TAK1-
binding protein 1 (TAB1),22 the full length microtubule
associated protein tau (isoform 2N4R),23 and calcium/
calmodulin-dependent protein kinase type IV (CaMKIV)24 as
substrates for the hOGT-catalyzed formation of O-Glc/O-
GlcNAc using UDP-[3H]Glc/UDP-[3H]GlcNAc as sugar
donors (Figure 2B). Curiously, among these four protein
substrates, which were modified using UDP-[3H]GlcNAc, only
Nup62 was modified by UDP-[3H]Glc. We also evaluated the
ability of OGT to use UDP-GlcNAc, UDP-Glc, and UDP-
GlcAz as donor substrates for the OGT catalyzed modification
of the known OGT peptide substrate CKII.14 Qualitatively,
OGT could modify CKII with UDP-GlcNAc and UDP-Glc,
though as expected, UDP-Glc is used less efficiently than UDP-
GlcNAc (Supporting Figure 3). We find that using these
conditions, OGT transfer using UDP-GlcAz as a donor
substrate for the CKII peptide was not detected, which may
stem from it being a poor substrate in vitro with this acceptor
peptide substrate. These observations suggest that O-Glc
modification catalyzed by OGT is relatively inefficient and
may (i) occur with some preference for certain protein
substrates, (ii) require other components only found in vivo
for efficient transfer, or (iii) occur at a slow rate such that it can
only be observed using excellent protein acceptor substrates.
Substrate Engineering Using GlcAz. Recent efforts have
enabled metabolic labeling of O-GlcNAc modified proteins in
cell culture.7,9−13,25 These sugar analogues make use of acetyled
precursor sugars that are deacylated within the cell by
endogenous esterases. Given the unusual observation that
UDP-GlcAz can serve as a substrate for hOGT, we set out to
establish whether UDP-GlcAz was formed in COS-7 cells
cultured with AcGlcAz (Supporting Figure 4A). Using capillary
electrophoresis (CE) to detect nucleotide sugars,16 we found
that COS-7 cells treated with 100 μM AcGlcAz produced two
nucleotide azido-sugars which could be detected after CuAAC
labeling with Fluor488-alkyne. One is UDP-GlcAz based on its
co-migration with a synthetic standard, and the other is thought
to be UDP-GalAz, converted from UDP-GlcAz by a UDP-
GlcNAc/Glc-epimerase to yield the expected relative levels
predicted to be produced by UDP-GlcNAc/Glc-epimerase.26
Treating cells with GlcAz or DMSO vehicle control resulted in
little to no labeling (Supporting Figure 5B), whereas AcGlcAz
led to dose-dependent labeling of cellular proteins (Figure 3A
and Supporting Figure 5C). We observed time-dependent
increases in protein labeling up to 16 h after AcGlcAz treatment
(Supporting Figure 5D). These time-dependent data suggest
preferential labeling of certain proteins that can be seen at early
time points. We find O-GlcAz is gradually lost from proteins
after changing the media (Supporting Figure 5E), presumably
either through enzymatic processing as suggested by our in vitro
studies (Figure 2A) or during their proteolytic degradation.
Notably, we observed a similar protein pattern in DMSO-
treated and 100 μM AcGlcAz-treated COS-7 lysates, but
different patterns were seen in lysates from cells treated with
250 μM AcGlcAz (Supporting Figure 5A), which is consistent
with concentrations of AcGlcAz ≥ 250 μM having marked
effects on cell morphology at 16 h.
To test if AcGlcAz influences O-GlcNAc levels, we
performed immunoblot analyses using anti-OGT and anti-O-
GlcNAc antibodies and found a decrease in both OGT and O-
GlcNAc levels upon AcGlcAz treatment at 16 h (Figure 3A).
Given the apparent decrease in O-GlcNAc levels, and because
OGT levels are known to drop upon increased cellular O-
GlcNAcylation,16 we speculated that accumulated O-GlcAz on
proteins may compete with O-GlcNAc. Alternatively, formation
of UDP-GlcAz may compete with UDP-GlcNAc levels, leading
to decreased UDP-GlcNAc levels upon AcGlcAz treatment and
consequent decreased O-GlcNAc levels that are independent of
O-GlcAz levels. Our CE analysis of UDP-GlcNAc, UDP-
GalNAc, UDP-Glc, and UDP-Gal levels within COS-7 cells
Figure 2. Characterization of the OGT catalyzed formation of O-Glc
and O-GlcNAz and their processing by hOGA and β-glucosidases in
vitro. (A) hOGT radiolabeled O-Glc and O-GlcNAc modified Nup62
were subjected to digestion by hOGA, sweet almond β-glucosidase,
and COS-7 cell lysates. (B) Assay of hOGT-catalyzed formation of O-
Glc using Nup62, TAB1, tau, and CaMKIV.
(Supporting Figure 4B) show that AcGlcAz has no significant
effect on the levels of these UDP-nucleotide sugars.
We next evaluated whether GlcAz is found on known targets
of OGT. We therefore immunoprecipitated the well-known
OGT target protein Nup62 from COS-7 cell lysates treated
with 100 μM AcGlcAz (Figure 3B). We find monoclonal
antibody mAb414, which targets nucleoporins containing FG
repeats including Nup62 and Nup153, immunoprecipitated
nucleoporins that could be labeled by CuAAC using a cleavable
alkyne-diazo-biotin probe and detected by streptavidin blotting.
The reverse experiment using CuAAC to first install the alkyne-
diazo-biotin and precipitate labeled proteins using streptavidin
yielded a pool of proteins in which we could detect Nup62 by
immunoblot using mAb414 (Figure 3C). These data provide
clear support for O-GlcAz labeling of nucleocytoplasmic
proteins upon metabolic feeding with AcGlcAz.
OGT Inhibition and Knockdown Reduce O-GlcAz. To
estimate the extent of OGT-dependent GlcAz incorporation
into nuclear and cytosolic proteins, we used both chemical and
genetic methods to reduce cellular OGT activity (Figure 3). We
used 1,3,4,6-tetra-O-acetyl-5-thio-α-D-glucopyranose (Ac5SGlc-
NAc) as a cell active OGT inhibitor to decrease OGT activity.16
Using mouse embryonic fibroblasts (MEFs)2 that regulate Cre-
recombinase in a tamoxifen-inducible manner, we induced site-
specific excision of the OGT gene and downstream loss of
OGT protein and O-GlcNAc. Treating MEF cells with
tamoxifen or Ac5SGlcNAc both resulted in a robust decrease
in O-GlcAz protein modification (Figure 4B). Deletion of OGT
from MEF cells was confirmed by decreases in both OGT and
O-GlcNAc levels (Figure 3). Next, we investigated whether
GlcAz is incorporated into N-linked glycans at significant levels
by using PNGase F digestion to remove glycoprotein N-
glycosylation in lysates from AcGlcAz-treated COS-7 cells. We
observed no reduction in the level of GlcAz-dependent protein-
linked azide groups. We also assessed the effects of AcGlcAz on
protein N-glycosylation levels and found there was a decrease in
the level of ConA reactivity in the AcGlcAz treated COS-7 cell
lysate, but we observed no change in WGA reactivity
(Supporting Figure 6). Similar to the effect of 2-deoxy-D-
glucose on cells,27 we speculate that AcGlcAz could reduce the
amount of dolicol-linked Glc and GlcNAc donors and thereby
impede early steps of N-glycan biosynthesis. Collectively, these
data suggest that GlcAz is not significantly incorporated into N-
glycans and does not result in major perturbations in nucleotide
sugar levels.
To evaluate the cellular locations at which GlcAz is
incorporated we fixed COS7 cells and then conjugated 5-
TAMRA-alkyne to azide moieties. We again noted that 250 μM
AcGlcAz led to changes in cell morphology that were consistent
with the observed perturbations in the cellular protein
composition (Supporting Figure 5A). At 100 μM AcGlcAz,
however, we observed no obvious morphological changes and
noted prominent protein labeling within the nucleocytoplasmic
space (Supporting Figure 7). Using MEF cells, we observed
similar effects at 100 μM AcGlcAz, with the majority of
fluorescence being localized to the nucleus and the nuclear
envelope (Figure 4A), which is consistent with nuclear pore
proteins being major targets of OGT.19,28 Interestingly, the O-
GlcAz signal forms punctuate structures having sizes ranging
from 0.8 to 1.2 μm that appear to be qualitatively coincident
with the Hoechst staining. AcGlcNAz labeling (100 μM)
observed using quantitative wide-field fluorescence microscopy
revealed a similar level of labeling to when using GlcAz (GlcAz,
100 ± 6 RFU/cell; GlcNAz, 95 ± 7 in RFU/cell). The
metabolic OGT inhibitor Ac5SGlcNAc caused a reduction in
O-GlcAz labeling (30 ± 2 RFU/cell) similar to that seen when
Figure 3. Characterization O-GlcAz labeling in whole cell lysates and on Nup62. (A) Dose-dependent effects of 16 h treatment with AcGlcAz (100
or 250 μM) on COS-7 cell labeling using CuAAC labeling with 5-TAMRA-alkyne. Effect of AcGlcAz on OGT and O-GlcNAc levels as assessed by
immunoblot. (B) Immunoprecipitation of Nup62 and Nup153 from COS-7 cells using mAb414 and their detection using mAb414 and CuAAC
conjugation to a biotin probe followed by streptavidin blotting. (C) CuAAC conjugation of lysates to a biotin probe followed by streptavidin
pulldown and probing using mAb414.
using this inhibitor with GlcNAz (21 ± 1 RFU/cell). Notably,
loss of O-GlcAz labeling was most pronounced within the
nucleus, leading to disappearance of the punctuate O-GlcAz-
labeled features. Tamoxifen-induced knockout of OGT in MEF
cells also decreased O-GlcAz and O-GlcNAz labeling (GlcAz,
100 ± 9 to 23 ± 3 RFU/cell; GlcNAz, 83 ± 10 to 23 ± 3 RFU/
cell) resembling that seen when using Ac5SGlcNAc. These data
provide strong support for GlcAz being incorporated
predominantly as O-GlcAz onto nuclear and cytoplasmic
proteins.
Proteomics of O-GlcAz Modified Proteins. To identify
O-GlcAz labeled proteins, we next adopted established
methods to chemoselectively enrich azide-tagged proteins,10
here using an alkyne-diazo-biotin cleavable probe and bound
resulting tagged proteins to streptavidin resin (Supporting
Figure 8). In parallel, we processed cells which had not been
treated with AcGlcAz. After releasing the proteins from the
probe with sodium dithionite and subjecting them to SDS-
PAGE, we proteolytically digested the samples and subjected
the resulting peptides to nanoLC-MS/MS analysis. Using this
approach, we identified 64 proteins in the experimental sample
using a 5% false positive threshold and only keratins and two
others in the control sample (Supporting Tables 1 and 2). All
of the identified proteins were nuclear or cytoplasmic, and all
but two are known O-GlcNAcylated proteins. Among these
proteins are two involved in carbohydrate metabolism, fructose-
bisphosphate aldolase A29 and pyruvate kinase PKM
(PKM2).30 We also observed several cytoskeletal proteins
including vimentin31 and mitochondrial proteins such as
voltage-dependent anion-selective channel protein 3
(VDAC3)32 (Supporting Figure 9). Notably, none of the
identified proteins were exclusively secretory proteins, which
supports that O-GlcAz predominantly occurs on nuclear and
cytoplasmic proteins.
Conclusions. Here, we found, surprisingly, that OGT can
use UDP-Glc as a donor substrate with a good acceptor protein
substrate such as Nup62.6,18 These data suggest that within
cells, the adventitious installation of glucose to form O-Glc
modified proteins may occur at low levels in a manner
analogous to the infrequent translational misincorporation seen
during protein synthesis.33 The extent of OGT-catalyzed
formation of O-Glc, as compared to O-GlcNAc, would be
Figure 4. Quantitative widefield fluorescence imaging of MEF cells treated with AcGlcAz and AcGlcNAz. Red indicates DAPI staining, and teal
indicates GlcAz-dependent fluorescence arising from CuAAC conjugation with 5-TAMRA-alkyne. (A) Effect of treatment with 5SGlcNAc (50 μM)
or excision of the OGT gene by tamoxifen (1.66 μM) on TAMRA fluorescence. The white bar at the left corner represents 10 μm. (B) Immunoblot
analysis of the effects in MEF cells of OGT gene excision induced by tamoxifen (1.66 μM) or inhibition of OGT inhibition by Ac5SGlcNAc (100
μM). (C) Quantitative analysis is carried out for each condition by dividing the TAMRA fluorescence by the number of cells in the field. All
measurements were made in quadruplicate.
governed by the ratio of the second order rate constants (kcat/
Km) for each of the donor sugar substrates multiplied by the
ratio of the nucleotide donor sugar concentrations. Accordingly,
with comparable levels of UDP-Glc and UDP-GlcNAc within
cells (Supporting Figure 4B), we would expect that one out of
every 25 O-GlcNAc residues on Nup62 would be replaced with
O-Glc. Notably, UDP-Glc is an abundant sugar nucleotide that
is biosynthesized from glucose and used in the synthesis of
glycogen, which acts as an energy reserve in specific tissues.
Levels of UDP-Glc therefore reflect glucose availability,34 and
levels can at times reach the hundred micromolar concentration
range within certain tissues.35 Accordingly, it seems possible
that O-Glc is a modification that cells may need to cope with
through the presence of a β-glucosidase having activity against
such a glycoconjugate. Consistent with a requirement for the 2-
acetamido group of the substrate for catalysis by hOGA,36 we
find that OGA cannot remove O-Glc. However, COS-7 lysates
catalyze the removal of O-Glc from modified Nup62, suggesting
a neutral β-glucosidase may be present within cells.
Accordingly, we speculate that further research may reveal
the presence of O-Glc within certain tissues having high UDP-
Glc to UDP-GlcNAc ratios.
Motivated by this in vitro promiscuity shown by OGT, we
showed that UDP-GlcAz was also a substrate in vitro for the
hOGT catalyzed modification of Nup62. We note that 2AzGlc
is unlikely to enter central metabolism since neither 2-deoxy-
nor 2-deoxy-2-fluoro-glucose are metabolized in this fashion.37
Instead, we found that metabolic feeding of cells with AcGlcAz
resulted in the formation of O-GlcAz conjugates within cells
that are localized primarily to nuclear and cytoplasmic proteins.
The use of both chemical and genetic methods to reduce OGT
activity supports GlcAz being incorporated within cells as O-
GlcAz conjugates. Nevertheless, it is possible that GlcAz can be
assimilated into glucose-containing glycoconjugates that were
not examined. Curiously, we observed OGT-dependent
formation of O-GlcAz conjugates in what appear to be
heterochromatic foci, consistent with proposed roles for
OGT in gene repression.38−40 We also noted the presence of
β-glucosidase activity within COS-7 lysates that is capable of
processing O-GlcAz from proteins, which is consistent with the
relatively rapid time-dependent decrease in O-GlcAz levels
observed upon removing this metabolic precursor from the
media. Notably, AcGlcAz treatments at 250 μM and above
show obvious cytotoxicity, which bears some similarity to
observations showing that 2-deoxy-D-glucopyranose (2-DG)
gives rise to cytotoxicity through multiple mechanisms.41,42
Worth noting in this regard is that 2-DG has been shown to
modulate O-GlcNAc levels43 through a mechanism that is not
well established, perhaps 2-DG is also incorporated onto
proteins at some level.27
It is interesting to speculate on the potential physiological
implications of these findings. UDP-Glc levels rise profoundly
upon increased glucose influx.34,44 In humans, the hepatic
assimilation rate of glucose into UDP-Glc increases from 0.2
mg/kg/min during fasting to 1.3−1.6 mg/kg/min on oral
feeding, and this represents approximately 20% of the
consumed carbohydrate load.45 Under such conditions,
increased OGT catalyzed modification of proteins with O-Glc
might occur, and such modification may play physiological roles
within cellular nutrient sensing pathways. This hypothesis,
however, remains speculative since O-Glc has not been
detected within cells and O-GlcAz formation and processing
may not reflect the potential cellular processing of O-Glc.
Accordingly, a method to detect the O-Glc modification within
cells could be of interest to address whether O-Glc is present
and, if so, whether it might occur within specific tissues at levels
consistent with function or at levels consistent with what might
be considered normal metabolic misincorporation. Finally, we
anticipate that AcGlcAz will serve, in a manner that is
complementary to other metabolic labeling reagents for O-
GlcNAc, as a useful chemical probe for cellular studies to
identify certain sets of protein that are particularly good
substrates for OGT.
■ METHODS
hOGT Assay. Nonradioactive hOGT assays were carried out using
100 μM UDP-GlcAz or UDP-GlcNAz, 10 μM recombinant Nup62,
and 1 μM hOGT at 37 °C for 2 h. The reactions were terminated by
the addition of 0.1 mM UDP.46 Click chemistry to couple the GlcAz-
and GlcNAz-labeled Nup62 using alkyne-diazo-biotin was performed
and detected using streptavidin IRdye. Radioactive hOGT assays were
performed, as described previously,6 using recombinant Nup62 as the
protein acceptor, and [3H]-UDP-GlcNAc (American Radiolabeled
Chemicals) or [3H]-UDP-Glc (American Radiolabeled Chemicals) as
the sugar donor. The specific activities of [3H]-UDP-GlcNAc and
[3H]-UDP-Glc were standardized to 4.3 Ci mmol−1. All assays were
done in at least triplicate. The counts in disintegrations per minute
(dpm) from scintillation counting were converted into rates (μmol of
GlcNAc min−1 mg−1 of hOGT) taking into account the length of time
for the assay and the enzyme concentration. The background rate in
the absence of enzyme was subtracted, and the resulting initial rates
were plotted against the substrate concentration using GRAFIT47 to
establish the apparent kcat and Km values for each substrate, which for
simplicity are referred to below as kcat and Km values. Radiolabeling of
recombinant Nup62, TAB1, CaMKIV, and tau (Isoform 2N4R) were
carried out using 100 μM of [3H]-UDP-GlcNAc or [3H]-UDP-Glc
with 4.3 Ci mmol−1 specific activity as the sugar donor, 10 μM protein
substrates, and 0.5 μM hOGT at 37 °C for 2 h. The reactions were
quenched with 0.1 mM UDP. Laemmli buffer was added to each of the
samples and subjected to SDS-PAGE and transferred onto a
nitrocellulose membrane. The membrane was air-dried before
exposure to a tritium phosphor imaging screen (GE Healthcare).
Four and 16 h exposures were scanned by a Typhoon Imager 8600
(Amersham) using the storage phosphor mode. The best contrast and
brightness of the figures were achieved using ImageQuant 5.2
(Molecular Dynamics).
Streptavidin Resin Capture. COS-7 cells in 25 cm2 plates were
allowed to grow to 80% confluency before being treated with either
100 μM AcGlcAz or AcGlcNAz for 16 h. Cell pellets were collected
and stored at 80 °C until required. Alkyne-diazo-biotin (0.5 mM) was
incubated with streptavidin agarose beads (ThermoFisher) for 2 h at 4
°C in PBS-T with 1% BSA. The resin was then washed with 6 × 1 mL
of PBS. Cell extracts were prepared by resuspending the cell pellet in a
lysis buffer (100 mM sodium phosphate, pH 7.5, 1% Nonidet P-40,
150 mM NaCl, and protease and phosphatase inhibitor cocktail
(Pierce)) and lysed by sonication. In order to remove the glycolipid
contamination, protein was precipitated from the total lysate by
chloroform/methanol precipitation. Precipitated proteins were
pelleted by centrifugation at 14 000 rpm for 5−10 min at RT and
washed twice with four volumes of methanol. The supernatant was
removed without disturbing the pellet, and the pellet was air-dried.
The protein pellet was dissolved in 1% SDS with heating and vortexing
and was then subjected to click chemistry by mixing with the alkyne-
diazo-biotin−streptavidin conjugated resin for 1 h at RT. The resin
was washed with 3 × 1 mL 1% SDS in PBS and 3 × 1 mL PBS and
then eluted using 100 mM sodium dithionite. The eluent was boiled
and vortexed in Laemmli sample buffer. Western blot analysis was
carried out on the samples to detect Nup62 using mAb414 antibody as
described above.
hOGA, β-Glucosidase, and COS-7 Cell Lysate Digestions.
Radiolabeling of recombinant Nup62 with [3H]-UDP-GlcNAc or
[3H]-UDP-Glc was carried out as described above. Recombinant
hOGA was dialyzed into PBS and concentrated to approximately 10
μM using a centrifugal concentrating device with a 30 kDa MW cutoff
(Amicon). β-Glucosidase from almond extract was purchased from
Sigma. The COS-7 cell lysate was prepared by cell harvesting as
described above. The cell pellet was resuspended in PBS with 0.1%
nonyl phenoxylpolyethoxylethanol (NP-40) substitute (Fluka) and
protease inhibitor cocktail (Roche). The lysate was then sonicated on
ice at 20% intensity for 10 s (Fisher Scientific, Model 500) and
centrifuged (13 000 rpm, 10 min, 4 °C) to remove insoluble debris.
The final concentration of enzymes and lysate used to digest 8 μM
[3H]-UDP-GlcNAc or [3H]-UDP-Glc labeled Nup62 were 2 μM
hOGA, 10 unit mL−1 β-glucosidase, and 0.2 mg mL−1 cell lysate. PBS
added to Nup62 samples was used as a control. After 2 h of incubation
at 37 °C, the reactions were terminated by the addition of Laemmli
sample buffer and analyzed by Typhoon Imager as described above.
Microscopy. COS-7 cells were plated into the central 60 wells of
glass-bottom 96-well plates (Corning 4580) before the addition of
AcGlcAz at 100 or 250 μM and incubation for 16 h. MEF cells were
plated into the central 60 wells of tissue culture treated cyclic olefin-
bottom 96-well plates (Corning 4680) and allowed to reach 60%
confluence before 1.66 μM tamoxifen citrate (Bioshop) or 50 μM
Ac5SGlcNAc was added to the cultures and incubated together for 24
h prior to the addition of either 100 μM AcGlcAz or AcGlcNAz and
incubation for a further 16 h. Cells were washed with 4 °C PBS and
fixed in a solution of 4% paraformaldehyde in PBS at 37 °C for 10 min.
The cells were then permeabilized using 0.3% Trixon X-100. Click
chemistry was carried using 5-carboxytetramethylrhodamine-alkyne
(5-TAMRA-Alkyne; Click Chemistry Tools) for 1 h as described in
the Supporting Methods. The cells were incubated with Hoechst
nucleus stain for 20 min followed by washing with PBS. The cells were
imaged using an ImageXpress Micro XLS Widefield High-Content
Analysis System (Molecular Device) equipped with an APO 40×
Nikon lens. TRITC (557/576 nm, Ex/Em) and Hoechst (352/461
nm, Ex/Em) channels were sequentially collected at 40× magnifica-
tion. Four fields of images were acquired at predefined regions of each
well of the microplate from each of three wells per treatment
condition. Data were analyzed using MetaExpress image analysis
software (Molecular Devices) by determining the total intensity
obtained from the RFP channel and dividing by the number of cells in
an individual field (containing at least 50 cells), chosen randomly from
two of the fields obtained per well, to yield a mean value for RFU per
cell (RFU/cell).
Additional Methods. Please see the Supporting Information for
detailed methods describing synthetic procedures, recombinant
protein expression and purification, cell culture, copper-catalyzed
azide−alkyne cycloaddition reactions, SDS-PAGE and immunoblot
analysis, immunoprecipitation of Nup62, hOGT assay using CKII
peptide as sugar acceptor PNGase F N-glycosylation digestion, analysis
of sugar nucleotides in cells by capillary electrophoresis, and mass
spectrometry proteomics.
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